SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (439)10/30/1998 9:28:00 AM
From: muddphudd  Read Replies (2) of 586
 
The issue about sepsis does not sound like a very big deal. Any invasive device (this column can be considered invasive, as is any plasmapheresis) has the risk of infection. How likely that is depends on the technique used and, as they mentioned, the equipment (tubes in this case). Since this column has been around for a decade I am not too concerned about that. If sepsis was a major problem for Prosorba we would have heard about it, it would have been reported (just like the Mayo Clinic pulled the plug on Redux).
The problem will be effective marketing and a partner. I hope they announce one soon. If they do not, the price will not hold.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News